From CNBC · Gerry Smith,Brad Quick · · 3m
Pompe drug shortage leaves patients without critical infusions
A three-month supply disruption of Sanofi's Pompe disease treatments has forced patients to cancel infusions, raising fears of irreversible health decline.
In brief
A three-month supply disruption of Sanofi's Pompe disease treatments has forced patients to cancel infusions, raising fears of irreversible health decline. Sanofi's Pompe disease drug shortage has lasted over three months due to manufacturing issues at its Ireland facility, forcing patients to miss critical infusions…
Sanofi's Pompe drug shortage drags on
A shortage of Sanofi's Pompe disease drugs has lasted more than three months, forcing patients to miss critical infusions. Shipping delays could interrupt infusions for some U.S. patients through the end of November.
What Pompe disease does to the body
About one in every nineteen thousand babies is born with Pompe disease. Patients lack an enzyme for breaking down a complex sugar, causing toxic glycogen buildup. Their muscles weaken and their heart can become enlarged.
How Sanofi's drugs work
Sanofi's Lumizyme and Nexviazyme replace the missing enzyme, protecting the patient's muscles. Patients typically receive Sanofi's drugs every two weeks. Left untreated, Pompe disease is often fatal.
Manufacturing problems at Ireland facility
Sanofi says the shortage results from issues at its manufacturing facility in Ireland.The FDA inspected the plant between January twelve and January twenty, twenty twenty-six and found violations.
Patients say Sanofi lacked transparency
Ryan Colburn, a person living with Pompe, says many patients were unaware of manufacturing issues and had no way to prepare.
“The lack of proactive transparency and apparent lack of buffer are of huge concern for any medicine that people's lives and well-being depend on access to.”
Monique Griffin's infusion was canceled

Monique Griffin, fifty-one, uses a wheelchair due to Pompe disease.Two weeks ago, Sanofi told her a shipping delay had interrupted supply of her drug.Her next infusion was canceled.
“You're basically letting the disease take over again. It's terrifying.”
A mother fears for her son's heart
Chelsey McGee's ten-year-old son Logan has taken Lumizyme every two weeks since he was diagnosed with Pompe disease as an infant.She is concerned that missing even one appointment will damage his heart.
Sanofi says it is prioritizing vulnerable patients
A Sanofi spokesperson said there were no issues with drug quality and the company is committed to ensuring that the most vulnerable patients receive treatment first during this period.
The short version
Sanofi's Pompe disease drug shortage has lasted over three months due to manufacturing issues at its Ireland facility, forcing patients to miss critical infusions and raising concerns about permanent health damage.
Read the TL;DR — this story on one card.





